IRLAB Therapeutics AB (publ)
Stockholm Stock Exchange IRLAB-A.ST
IRLAB Therapeutics AB (publ) EPS (Diluted) for the year ending December 31, 2023: USD -0.34
-
IRLAB Therapeutics AB (publ) EPS (Diluted) for the year ending December 31, 2022 was USD -0.21, a -290.83% change year over year.
-
IRLAB Therapeutics AB (publ) EPS (Diluted) for the year ending December 31, 2021 was USD 0.11, a 147.07% change year over year.
-
IRLAB Therapeutics AB (publ) EPS (Diluted) for the year ending December 31, 2020 was USD -0.23, a 5.65% change year over year.
-
IRLAB Therapeutics AB (publ) EPS (Diluted) for the year ending December 31, 2019 was USD -0.25, a -15.98% change year over year.
| Date | EPS (Diluted) | Shares (Diluted, Weighted) | Shares (Basic, Weighted) | Revenue |
|---|
| CEO | Dr. Kristina Torfgard Ph.D. |
| IPO Date | Feb. 28, 2017 |
| Location | Sweden |
| Headquarters | Arvid Wallgrens Backe 20 |
| Employees | 32 |
| Sector | Health Care |
| Industries | |
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Past 5 years
USD 17.87
USD 2.74
USD 0.15
USD 0.83
StockViz Staff
January 15, 2025
Any question? Send us an email